Department of Nephrology-Transplantation, Necker Enfants Malades Hospital, APHP, Paris, France.
INSERM U1151, Necker Institute, Necker Enfants Malades Hospital, APHP, Paris, France.
Transpl Infect Dis. 2021 Jun;23(3):e13552. doi: 10.1111/tid.13552. Epub 2021 Jan 4.
EBV-positive mucocutaneous ulcer (EBV-MCU) is a rare EBV-positive B-cell lymphoproliferative disorder occurring in immunocompromised patients such as patients with solid organ or hematopoietic stem cells transplantation. EBV-MCU often consists of an isolated and circumscribed cutaneous or mucosal ulcerative lesion with a self-limited growth potential and a high regression rate upon immunosuppressive treatment withdrawal or rituximab therapy. Nevertheless, the pathophysiology of this latent infection leading to clonal lymphoproliferation is not well established. We report here two cases of EBV-MCU in kidney transplant recipients with a dissociated immune response to EBV with the absence of EBV-related antibodies and a positive T-cell response to EBV suggesting a potential specific oncogenic mechanism in this lymphoproliferative disorder.
EBV 阳性黏膜溃疡（EBV-MCU）是一种罕见的 EBV 阳性 B 细胞淋巴增生性疾病，发生于免疫功能低下的患者，如实体器官或造血干细胞移植患者。EBV-MCU 通常由孤立性和局限性皮肤或黏膜溃疡性病变组成，具有自限性生长潜力，在免疫抑制治疗停药或利妥昔单抗治疗后，其消退率较高。然而，导致这种潜伏感染导致克隆性淋巴增生的病理生理学机制尚未完全确立。我们在此报告两例 EBV-MCU 病例，发生于肾移植受者中，其对 EBV 的免疫反应分离，缺乏 EBV 相关抗体，而对 EBV 的 T 细胞反应阳性，提示在这种淋巴增生性疾病中存在潜在的特定致癌机制。
